Mga Batayang Estadistika
| CIK | 1576885 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Acumen Pharmaceuticals, Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| August 12, 2025 |
acumenncxcorporatexdeck Corporate Presentation August 2025 1 Forward-Looking Statements 2 This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. |
|
| August 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fromto Commission File Number: 001-40551 Acumen Pharmaceuticals, Inc. |
|
| August 12, 2025 |
acumenjcrcollaborationop Exhibit 10.1 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED COLLABORATION, OPTION, AND LICENSE AGREEMENT BY AND BETWEEN ACUMEN PHARMACEUTICALS, INC. AND JCR PHARMACEUTICALS CO., LTD. JULY 15, 2025 i TABLE OF CONTENTS 1. DEF |
|
| August 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2025 Acumen Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40551 36-4108129 (State or Other Jurisdiction of Incorporation) (Commi |
|
| August 12, 2025 |
Acumen Pharmaceuticals Reports Second Quarter 2025 Financial Results and Business Highlights Exhibit 99.1 Acumen Pharmaceuticals Reports Second Quarter 2025 Financial Results and Business Highlights •Expect to report topline results for ALTITUDE-AD, a Phase 2 study to investigate sabirnetug (ACU193) for the treatment of early Alzheimer’s disease, in late 2026 •Expect decision to advance an oligomer-targeted Enhanced Brain DeliveryTM product candidate in early 2026 •Cash, cash equivalents |
|
| July 15, 2025 |
acumenncxcorporatexdeck Corporate Presentation July 2025 1 Forward-Looking Statements 2 This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. |
|
| July 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 15, 2025 Acumen Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40551 36-4108129 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| June 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 4, 2025 Acumen Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40551 36-4108129 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| May 13, 2025 |
acumenncxcorporatexdeck Corporate Presentation May 2025 1 Forward-Looking Statements 2 This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. |
|
| May 13, 2025 |
Executive Employment Agreement, by and between the Re Exhibit 10.1 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (the “Agreement”) is entered into effective February 1, 2024 (the “Effective Date”), by and between James Doherty, PhD (the “Executive”) and Acumen Pharmaceuticals, Inc. (the “Company”). WHEREAS, the Company desires to employ Executive and, in connection therewith, to compensate Executive for Executive’s personal services to the Company; |
|
| May 13, 2025 |
Acumen Pharmaceuticals Reports First Quarter 2025 Financial Results and Business Highlights Exhibit 99.1 Acumen Pharmaceuticals Reports First Quarter 2025 Financial Results and Business Highlights •Expect to report topline results for ALTITUDE-AD, a Phase 2 study to investigate sabirnetug (ACU193) for the treatment of early Alzheimer’s disease, in late 2026 •Cash, cash equivalents and marketable securities of $197.9 million as of March 31, 2025, expected to support current clinical and o |
|
| May 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2025 Acumen Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40551 36-4108129 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| May 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fromto Commission File Number: 001-40551 Acumen Pharmaceuticals, Inc. |
|
| April 23, 2025 |
SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Definitive Proxy Statement x Definitive Additional Materials o Soliciting Material Pursuant to § 240. |
|
| April 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Definitive Proxy State |
|
| March 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 27, 2025 Acumen Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40551 36-4108129 (State or Other Jurisdiction of Incorporation) (Commis |
|
| March 27, 2025 |
Lease Agreement, by and between the Registrant and Price-Poore House, LLC, dated August 1, 2024. Exhibit 10.11 LEASE AGREEMENT This Lease made as of the 1st day of August 2024, between Price-Poore House, LLC (herein “Lessor”), and Acumen Pharmaceuticals, Inc. (herein “Lessee”). In consideration of the mutual covenants contained herein, the parties agree as follows: 1.DESCRIPTION OF PREMISES. Lessor leases to Lessee a portion of the premises located at 427 Park Street, Charlottesville, Virgini |
|
| March 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K x Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended: December 31, 2024 or o Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 FOR THE TRANSITION PERIOD FROM TO Commission file number: 001-40551 Acumen |
|
| March 27, 2025 |
Amended and Restated Non-Employee Director Compensation Policy. Exhibit 10.4 ACUMEN PHARMACEUTICALS, INC. NON-EMPLOYEE DIRECTOR COMPENSATION POLICY ORIGINALLY ADOPTED BY THE BOARD OF DIRECTORS: Effective June 30, 2021 AMENDED BY THE BOARD OF DIRECTORS: March 24, 2022 AMENDED BY THE BOARD OF DIRECTORS: March 6, 2025 Each member of the Board of Directors (the “Board”) who is not also serving as an employee of Acumen Pharmaceuticals, Inc. (the “Company”) or any o |
|
| March 27, 2025 |
Exhibit 19.1 ACUMEN PHARMACEUTICALS, INC. AMENDED AND RESTATED INSIDER TRADING POLICY (AS OF JANUARY 1, 2024) INTRODUCTION During the course of your relationship with Acumen Pharmaceuticals, Inc. (the “Company”), you may receive material information that is not yet publicly available about the Company or other publicly traded companies with which the Company has business relationships. Material, n |
|
| March 27, 2025 |
Corporate Presentation March 2025 1 Forward-Looking Statements 2 This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. |
|
| March 27, 2025 |
Exhibit 99.1 Acumen Pharmaceuticals Reports Financial Results for the Year Ended December 31, 2024 and Business Highlights •Enrollment complete for ALTITUDE-AD, a Phase 2 study to investigate sabirnetug (ACU193) for the treatment of early Alzheimer’s disease ◦Anticipate topline results in late 2026 •Topline results from the Phase 1 study investigating a subcutaneous sabirnetug formulation support |
|
| March 27, 2025 |
Exhibit 107 CALCULATION OF FILING FEE TABLES Form S-8 (Form Type) Acumen Pharmaceuticals, Inc. |
|
| March 27, 2025 |
As filed with the Securities and Exchange Commission on March 27, 2025 As filed with the Securities and Exchange Commission on March 27, 2025 Registration No. |
|
| November 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2024 Acumen Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40551 36-4108129 (State or Other Jurisdiction of Incorporation) (Com |
|
| November 12, 2024 |
Corporate Presentation November 2024 1 Forward-Looking Statements 2 This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. |
|
| November 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fromto Commission File Number: 001-40551 Acumen Pharmaceuticals, Inc. |
|
| November 12, 2024 |
Acumen Pharmaceuticals Reports Third Quarter 2024 Financial Results and Business Highlights Exhibit 99.1 Acumen Pharmaceuticals Reports Third Quarter 2024 Financial Results and Business Highlights •Expect ALTITUDE-AD, a Phase 2 study to investigate sabirnetug (ACU193) for the treatment of early Alzheimer’s disease, to complete enrollment in the first half of 2025 •Expect to announce topline results of Phase 1 study to support subcutaneous administration of sabirnetug in the first quarter |
|
| August 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 13, 2024 Acumen Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40551 36-4108129 (State or Other Jurisdiction of Incorporation) (Commi |
|
| August 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fromto Commission File Number: 001-40551 Acumen Pharmaceuticals, Inc. |
|
| August 13, 2024 |
Acumen Pharmaceuticals Reports Second Quarter 2024 Financial Results and Business Highlights Exhibit 99.1 Acumen Pharmaceuticals Reports Second Quarter 2024 Financial Results and Business Highlights •Actively enrolling subjects in ALTITUDE-AD, a Phase 2 study to investigate sabirnetug (ACU193) for the treatment of early Alzheimer’s disease •Dosed the first subject in a Phase 1 study to support subcutaneous administration of sabirnetug in July 2024 with topline results anticipated in the f |
|
| August 13, 2024 |
Corporate Presentation August 2024 1 Exhibit 99.2 Forward-Looking Statements 2 This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Any statement describing Acumen’s goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Word |
|
| June 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 4, 2024 Acumen Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40551 36-4108129 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| May 14, 2024 |
acumenncxcorporatexdeck Corporate Presentation May 2024 1 Exhibit 99.2 Forward-Looking Statements 2 This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Any statement describing Acumen’s goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at |
|
| May 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2024 Acumen Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40551 36-4108129 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| May 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fromto Commission File Number: 001-40551 Acumen Pharmaceuticals, Inc. |
|
| May 14, 2024 |
Acumen Pharmaceuticals Reports First Quarter 2024 Financial Results and Business Highlights Exhibit 99.1 Acumen Pharmaceuticals Reports First Quarter 2024 Financial Results and Business Highlights •Announced initiation of ALTITUDE-AD, a Phase 2 study to investigate sabirnetug (ACU193) for the treatment of early Alzheimer’s disease, in May 2024 •Initiation of a Phase 1 study to support a subcutaneous dosing option of sabirnetug expected in mid-2024 •Cash, cash equivalents and marketable s |
|
| April 22, 2024 |
ACUMEN PHARMACEUTICALS, INC. 427 Park Street Charlottesville, VA 22902 ACUMEN PHARMACEUTICALS, INC. 427 Park Street Charlottesville, VA 22902 April 22, 2024 VIA EDGAR Securities and Exchange Commission Division of Corporate Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Doris Gama Re: Acumen Pharmaceuticals, Inc. Registration Statement on Form S-3 (File No. 333-278280) Request for Acceleration Ladies and Gentlemen: Pursuant to Rule 461 under the Securit |
|
| April 22, 2024 |
SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Definitive Proxy Statement o Definitive Additional Materials o Soliciting Material Pursuant to § 240. |
|
| April 22, 2024 |
SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Definitive Proxy Statement x Definitive Additional Materials o Soliciting Material Pursuant to § 240. |
|
| March 27, 2024 |
Form of Preferred Stock Warrant Agreement and Warrant Certificate. Exhibit 4.5 ACUMEN PHARMACEUTICALS, INC. AND , AS WARRANT AGENT FORM OF PREFERRED STOCK WARRANT AGREEMENT DATED AS OF TABLE OF CONTENTS ARTICLE 1 ISSUANCE OF WARRANTS AND EXECUTION AND DELIVERY OF WARRANT CERTIFICATES 1 1.1 Issuance of Warrants 1 1.2 Execution and Delivery of Warrant Certificates 1 1.3 Issuance of Warrant Certificates 2 ARTICLE 2 WARRANT PRICE, DURATION AND EXERCISE OF WARRANTS 2 |
|
| March 27, 2024 |
Form of Indenture, between the Registrant and one or more trustees to be named. Exhibit 4.2 ACUMEN PHARMACEUTICALS, INC., ISSUER AND [TRUSTEE], TRUSTEE INDENTURE DATED AS OF [•], 20 DEBT SECURITIES TABLE OF CONTENTS ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 5 Section 2.01 Designation and Terms of Securities 5 Section 2.02 Form of Securities and Trustee’s Certificate 8 Sec |
|
| March 27, 2024 |
Form of Common Stock Warrant Agreement and Warrant Certificate. Exhibit 4.4 ACUMEN PHARMACEUTICALS, INC. AND , AS WARRANT AGENT FORM OF COMMON STOCK WARRANT AGREEMENT DATED AS OF ACUMEN PHARMACEUTICALS, INC. FORM OF COMMON STOCK WARRANT AGREEMENT This COMMON STOCK WARRANT AGREEMENT (this “Agreement”), dated as of [•], between ACUMEN PHARMACEUTICALS, INC., a Delaware corporation (the “Company”), and [•], a [corporation] [national banking association] organized |
|
| March 27, 2024 |
Exhibit 107 CALCULATION OF FILING FEE TABLES Form S-8 Acumen Pharmaceuticals, Inc. |
|
| March 27, 2024 |
As filed with the Securities and Exchange Commission on March 27, 2024 As filed with the Securities and Exchange Commission on March 27, 2024 Registration No. |
|
| March 27, 2024 |
Form of Debt Securities Warrant Agreement and Warrant Certificate. Exhibit 4.6 ACUMEN PHARMACEUTICALS, INC. AND , AS WARRANT AGENT FORM OF DEBT SECURITIES WARRANT AGREEMENT DATED AS OF ACUMEN PHARMACEUTICALS, INC. FORM OF DEBT SECURITIES WARRANT AGREEMENT This DEBT SECURITIES WARRANT AGREEMENT (this “Agreement”), dated as of [•], between ACUMEN PHARMACEUTICALS, INC., a Delaware corporation (the “Company”), and [•], a [corporation] [national banking association] o |
|
| March 27, 2024 |
As filed with the Securities and Exchange Commission on March 27, 2024 As filed with the Securities and Exchange Commission on March 27, 2024 Registration No. |
|
| March 27, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Acumen Pharmaceuticals, Inc. |
|
| March 26, 2024 |
gistrant and Halozyme, Inc., dated November 5, 2023 Exhibit 10.15 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED NON-EXCLUSIVE COLLABORATION AND LICENSE AGREEMENT THIS NON-EXCLUSIVE COLLABORATION AND LICENSE AGREEMENT (this “Agreement”), effective as of November 5, 2023 (the “Effective Date”) is ent |
|
| March 26, 2024 |
coupment of Incentive Compensation. Exhibit 97.1 ACUMEN PHARMACEUTICALS, INC. POLICY FOR RECOUPMENT OF INCENTIVE COMPENSATION 1.Introduction In accordance with Section 10D of the Securities Exchange Act of 1934, as amended, and the regulations thereunder, the Board of Directors (the “Board”) of Acumen Pharmaceuticals, Inc. (the “Company”) has adopted a policy (the “Policy”) providing for the Company’s recoupment of certain incentive |
|
| March 26, 2024 |
Lease, by and between Registrant and DIV Washington, LLC, dated September 11, 2023 LEASE between DIV WASHINGTO�, LLC as Landlord And ACUMEN PHARMACEUTICALS, INC. as Tenant 1210-1220 Washington Street Newton, Massachusetts As of September 11, 2023 Exhibit 10.13 TABLE OF CONTENTS ARTICLE 1. GRANT .............................................................................................................................. 1 ARTICLE 2. TERM .......................................... |
|
| March 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 26, 2024 Acumen Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40551 36-4108129 (State or Other Jurisdiction of Incorporation) (Commis |
|
| March 26, 2024 |
1 Acumen Pharmaceuticals Reports Financial Results for the Year Ended December 31, 2023 and Business Highlights • Initiation of a Phase 2 study, ALTITUDE-AD, to investigate sabirnetug (ACU193) for the treatment of early Alzheimer’s disease expected in the first half of 2024 • Initiation of a Phase 1 study to support a subcutaneous dosing option of sabirnetug expected in mid- 2024 • Cash, cash equivalents and marketable securities of $306. |
|
| March 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K x Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended: December 31, 2023 or o Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 FOR THE TRANSITION PERIOD FROM TO Commission file number: 001-40551 Acumen |
|
| March 26, 2024 |
Loan and Security Agreement by and among the Registrant and the lenders party thereto, K2 LOAN AND SECURITY AGREEMENT This LOAN AND SECURITY AGREEMENT (as amended, restated, supplemented or otherwise modified from time to time, this “Agreement”) dated as of November 10, 2023 (the “Closing Date”) is entered into among ACUMEN PHARMACEUTICALS, INC. |
|
| March 19, 2024 |
acumenncxcorporatexdeck Corporate Presentation March 2024 1 Forward-Looking Statements 2 This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. |
|
| March 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 19, 2024 Acumen Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40551 36-4108129 (State or Other Jurisdiction of Incorporation) (Commis |
|
| February 14, 2024 |
ABOS / Acumen Pharmaceuticals, Inc. / Deep Track Capital, LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 6, 2024 |
ABOS / Acumen Pharmaceuticals, Inc. / FRANKLIN RESOURCES INC Passive Investment acum23in.htm - Generated by SEC Publisher for SEC Filing CUSIP NO. 00509G209 13G Page 1 of 14 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Acumen Pharmaceuticals, Inc (Name of Issuer) Common stock, par value $0.0001 per share (Title of Class of Securities) 00509G209 (CUSIP Number) December 31, 2023 |
|
| February 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 1, 2024 Acumen Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40551 36-4108129 (State or Other Jurisdiction of Incorporation) (Comm |
|
| February 1, 2024 |
Acumen Pharmaceuticals Appoints Dr. James Doherty as President and Chief Development Officer CHARLOTTESVILLE, VA, Feb. 1, 2024 – Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer’s disease, announced today the appointment of James Doherty, Ph.D., as |
|
| January 24, 2024 |
ABOS / Acumen Pharmaceuticals, Inc. / MURRAY JAMES B JR - SC 13G/A Passive Investment SC 13G/A 1 d799844dsc13ga.htm SC 13G/A SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1)* Acumen Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 00509G209 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the app |
|
| January 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 12, 2024 Acumen Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40551 36-4108129 (State or Other Jurisdiction of Incorporation) (Comm |
|
| January 12, 2024 |
Corporate Presentation January 2024 1 Forward-Looking Statements 2 This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. |
|
| January 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 8, 2024 Acumen Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40551 36-4108129 (State or Other Jurisdiction of Incorporation) (Commi |
|
| January 8, 2024 |
abosjpmslides15245pmnoap J.P. Morgan Healthcare Conference January 8, 2024 1 Dan O’Connell, CEO Forward-Looking Statements 2 This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Any statement describing Acumen’s goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and s |
|
| December 4, 2023 |
Corporate Presentation December 2023 1 Forward-Looking Statements 2 This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. |
|
| December 4, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 4, 2023 Acumen Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40551 36-4108129 (State or Other Jurisdiction of Incorporation) (Comm |
|
| November 13, 2023 |
acumenncxcorporatexdeck Corporate Presentation November 2023 1 Forward-Looking Statements 2 This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. |
|
| November 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fromto Commission File Number: 001-40551 Acumen Pharmaceuticals, Inc. |
|
| November 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2023 Acumen Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40551 36-4108129 (State or Other Jurisdiction of Incorporation) (Com |
|
| November 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2023 Acumen Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40551 36-4108129 (State or Other Jurisdiction of Incorporation) (Com |
|
| November 13, 2023 |
Exhibit 99.2 Acumen Pharmaceuticals Secures $50.0 Million Credit Facility with K2 HealthVentures •Provides additional capital to support development of a subcutaneous formulation of ACU193 and general corporate purposes •$30 million drawn down at loan closing Charlottesville, VA., Nov. 13, 2023 – Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceu |
|
| November 13, 2023 |
Acumen Pharmaceuticals Reports Third Quarter 2023 Financial Results and Business Highlights Exhibit 99.1 Acumen Pharmaceuticals Reports Third Quarter 2023 Financial Results and Business Highlights •Initiation of a Phase 2 study, ALTITUDE-AD, to investigate ACU193 for the treatment of early Alzheimer’s disease expected in the first half of 2024, following positive FDA interaction in October 2023 •Announced global collaboration and license agreement with Halozyme for development of a subcu |
|
| November 9, 2023 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 5, 2023 Acumen Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40551 36-4108129 (State or Other Jurisdiction of Incorporation) (Comm |
|
| August 8, 2023 |
active137716350x1xabosx Exhibit 10.1 SECOND AMENDED AND RESTATED EMPLOYMENT AGREEMENT This SECOND AMENDED AND RESTATED EMPLOYMENT AGREEMENT (the “Agreement”) is entered into effective August 8, 2023 (the “Effective Date”), by and between Eric Siemers, MD (“Executive”) and Acumen Pharmaceuticals, Inc. (the “Company” and, together with Executive, the “Parties”) and supersedes and replaces any prior |
|
| August 8, 2023 |
acumenncxcorporatexdeck Corporate Presentation August 2023 1 Forward-Looking Statements 2 This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. |
|
| August 8, 2023 |
Acumen Pharmaceuticals Reports Second Quarter 2023 Financial Results and Business Highlights Exhibit 99.1 Acumen Pharmaceuticals Reports Second Quarter 2023 Financial Results and Business Highlights •Positive INTERCEPT-AD Phase 1 trial results announced in July 2023 demonstrate ACU193’s potential as a differentiated antibody for the treatment of early Alzheimer’s disease •Cash, cash equivalents and marketable securities of $172.2 million as of June 30, 2023 bolstered by an additional $122 |
|
| August 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fromto Commission File Number: 001-40551 Acumen Pharmaceuticals, Inc. |
|
| August 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2023 Acumen Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40551 36-4108129 (State or Other Jurisdiction of Incorporation) (Commis |
|
| July 25, 2023 |
ABOS / Acumen Pharmaceuticals Inc / RA CAPITAL MANAGEMENT, L.P. - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Acumen Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 00509G209 (CUSIP Number) RA Capital Management, L.P. 200 Berkeley Street, 18th Floor Boston, MA 02116 Attn: Peter Kolchinsky Telephon |
|
| July 20, 2023 |
16,774,193 Shares Common Stock 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-266004 PROSPECTUS SUPPLEMENT (To prospectus dated July 8, 2022) 16,774,193 Shares Common Stock We are offering 16,774,193 shares of our common stock. Our common stock is listed on The Nasdaq Global Select Market under the symbol “ABOS.” On July 18, 2023, the last reported sale price of our common stock as reported on The |
|
| July 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 18, 2023 Acumen Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40551 36-4108129 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| July 20, 2023 |
PART II INFORMATION NOT REQUIRED IN PROSPECTUS EX-99.1 Exhibit 99.1 PART II INFORMATION NOT REQUIRED IN PROSPECTUS Item 14. Other Expenses of Issuance and Distribution. The following table sets forth estimates of the various expenses, other than any underwriting discounts and commissions, in connection with the sale and distribution of the securities being registered. SEC Registration Fee $ 18,540 FINRA filing fee 30,500 Accounting fees and ex |
|
| July 20, 2023 |
EX-1.1 Exhibit 1.1 ACUMEN PHARMACEUTICALS, INC. (a Delaware corporation) 16,774,193 Shares of Common Stock UNDERWRITING AGREEMENT Dated: July 18, 2023 ACUMEN PHARMACEUTICALS, INC. (a Delaware Corporation) 16,774,193 Shares of Common Stock UNDERWRITING AGREEMENT July 18, 2023 BofA Securities, Inc. Citigroup Global Markets Inc. Stifel, Nicolaus & Company, Incorporated as Representatives of the sever |
|
| July 17, 2023 |
SUBJECT TO COMPLETION, DATED JULY 17, 2023 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-266004 The information contained in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has become effective by rule of the Securities and Exchange Commission. This preliminary prospectus supplement and the accompanying prospectus are not an off |
|
| July 17, 2023 |
EX-99.2 Investor Conference Call to Discuss INTERCEPT-AD Results July 17, 2023 Exhibit 99.2 Forward-Looking Statements This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Any statement describing Acumen’s goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should |
|
| July 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 17, 2023 Acumen Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40551 36-4108129 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| July 17, 2023 |
EX-99.1 Exhibit 99.1 Acumen Pharmaceuticals Presents Positive Topline Results from First-in-Human Phase 1 Study of ACU193 for Early Alzheimer’s Disease at the Alzheimer’s Association International Conference (AAIC) 2023 • Topline results from INTERCEPT-AD trial met primary and secondary objectives, demonstrating proof-of-mechanism for ACU193, the first clinical-stage amyloid beta oligomer (AßO)-ta |
|
| July 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 16, 2023 Acumen Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40551 36-4108129 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| June 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 6, 2023 Acumen Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40551 36-4108129 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| June 8, 2023 |
active136401491x1xacume Exhibit 3.1 1364014911 ACUMEN PHARMACEUTICALS, INC. AMENDED AND RESTATED CERTIFICATE OF INCORPORATION Acumen Pharmaceuticals, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Company”), does hereby certify as follows: FIRST: That the name of this corporation is Acumen Pharmaceuticals, Inc. The original Certificate of Incorporation of |
|
| May 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fromto Commission File Number: 001-40551 Acumen Pharmaceuticals, Inc. |
|
| May 9, 2023 |
acumenncxcorporatexdeck Corporate Presentation May 2023 1 Forward-Looking Statements 2 This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. |
|
| May 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2023 Acumen Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40551 36-4108129 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| May 9, 2023 |
acumen-xamendedxandxres AMENDED AND RESTATED EMPLOYMENT AGREEMENT This AMENDED AND RESTATED EMPLOYMENT AGREEMENT (the “Agreement”) is entered into effective January 1, 2023 (the “Effective Date”), by and between Derek Meisner (the “Executive”) and Acumen Pharmaceuticals, Inc. |
|
| May 9, 2023 |
Acumen Pharmaceuticals Reports First Quarter 2023 Financial Results and Business Highlights Exhibit 99.1 Acumen Pharmaceuticals Reports First Quarter 2023 Financial Results and Business Highlights •Expect to report topline results from INTERCEPT-AD, a Phase 1 clinical trial of ACU193 in patients with early Alzheimer’s disease, in the third quarter of 2023 •Cash, cash equivalents and marketable securities of $183.8 million as of March 31, 2023 expected to be sufficient to support clinical |
|
| April 28, 2023 |
SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| April 27, 2023 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 27, 2023 Acumen Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40551 36-4108129 (State or Other Jurisdiction of Incorporation) (Commis |
|
| April 27, 2023 |
Up to $50,000,000 of Shares Common Stock 424B5 Filed Pursuant to Rule 424(b)(5) Registration Statement No. 333-266004 Supplement dated April 27, 2023 To Prospectus dated July 1, 2022 Up to $50,000,000 of Shares Common Stock This prospectus supplement, or Prospectus Supplement, supplements certain information contained in the sales agreement prospectus dated July 1, 2022, or the Sales Agreement Prospectus, relating to the offer and sale o |
|
| April 27, 2023 |
EX-1.1 Exhibit 1.1 [Execution Version] ACUMEN PHARMACEUTICALS, INC. Common Stock ($0.0001 par value) AMENDMENT NO. 1 TO THE ATM EQUITY OFFERINGSM SALES AGREEMENT April 27, 2023 BofA Securities, Inc. One Bryant Park New York, New York 10036 Stifel, Nicolaus & Company, Incorporated 787 Seventh Avenue, 11th Floor New York, New York 10019 BTIG, LLC 65 East 55th Street New York, NY 10022 Ladies and Gen |
|
| April 27, 2023 |
SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 DEF 14A Table of Contents SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy Statement ☐ Definitive Additional Materials ☐ Soliciting Material Pursuant to § 240. |
|
| April 14, 2023 |
SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Table of Contents SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Statement ☐ Definitive Additional Materials ☐ Soliciting Material Pursuant to § 240. |
|
| March 28, 2023 |
As filed with the Securities and Exchange Commission on March 28, 2023 As filed with the Securities and Exchange Commission on March 28, 2023 Registration No. |
|
| March 28, 2023 |
Exhibit 107 CALCULATION OF FILING FEE TABLES Form S-8 Acumen Pharmaceuticals, Inc. |
|
| March 27, 2023 |
Lease Agreement, by and between the Registrant and Price-Poore House, LLC, dated December 1, 2022. Exhibit 10.12 LEASE AGREEMENT This Lease made as of the 1 day of December 2022, between Price-Poore House, LLC (herein “Lessor”), and Acumen Pharmaceuticals Inc. (herein “Lessee”). In consideration of the mutual covenants contained herein, the parties agree as follows: 1.DESCRIPTION OF PREMISES. Lessor leases to Lessee a portion of the premises located at 427 Park Street, Charlottesville, Virginia |
|
| March 27, 2023 |
Lease Agreement, by and between the Registrant and Price-Poore House, LLC, dated September 28, 2022 Exhibit 10.11 LEASE AGREEMENT This Lease made as of the 28th day of September 2022, between Price-Poore House, LLC (herein “Lessor”), and Acumen Pharmaceuticals Inc. (herein “Lessee”). In consideration of the mutual covenants contained herein, the parties agree as follows: 1.DESCRIPTION OF PREMISES. Lessor leases to Lessee a portion of the premises located at 427 Park Street, Charlottesville, Virg |
|
| March 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 27, 2023 Acumen Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40551 36-4108129 (State or Other Jurisdiction of Incorporation) (Commis |
|
| March 27, 2023 |
acumenncxcorporatexdeck Corporate Presentation March 2023 1 Forward-Looking Statements 2 This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. |
|
| March 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K x Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended: December 31, 2022 or o Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 FOR THE TRANSITION PERIOD FROM TO Commission file number: 001-40551 Acumen |
|
| March 27, 2023 |
License Agreement, by and between the Registrant and Lonza Sales AG, dated November 2, 2022. Exhibit 10.1 CONFIDENTIAL GS SV LICENCE ROW CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL LICENCE AGREEMENT between LONZA SALES AG and ACUMEN PHARMACEUTICALS, INC. 1 [***] CONFIDENTIAL INDEX ARTICLE TITLE PAGE 1. Definitions and Interpretation 3 2. |
|
| March 27, 2023 |
Exhibit 99.1 Acumen Pharmaceuticals Reports Financial Results for Full Year Ended December 31, 2022 and Business Highlights •INTERCEPT-AD, a Phase 1 clinical trial of ACU193 in patients with early Alzheimer’s disease completed enrollment in February 2023 ◦Topline data expected in the third quarter of 2023 •Cash, cash equivalents and marketable securities of $193.4 million as of Dec. 31, 2022 expec |
|
| March 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 9, 2023 Acumen Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40551 36-4108129 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| March 15, 2023 |
Exhibit 3.1 AMENDED AND RESTATED BYLAWS OF ACUMEN PHARMACEUTICALS, INC. (A DELAWARE CORPORATION) March 9, 2023 ACUMEN PHARMACEUTICALS, INC. AMENDED AND RESTATED BYLAWS ARTICLE I OFFICES Section 1. Registered Office. The registered office shall be established and maintained at the office of Corporation Service Company, 251 Little Falls Drive, in the city of Wilmington, county of New Castle, Delawar |
|
| February 14, 2023 |
ABOS / Acumen Pharmaceuticals, Inc. / Deep Track Capital, LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 14, 2023 |
ABOS / Acumen Pharmaceuticals, Inc. / Manning Paul B - AMENDMENT TO FORM SC 13G Passive Investment SC 13G/A 1 abos-sc13ga123122.htm AMENDMENT TO FORM SC 13G SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO §240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO §240.13d-2 (Amendment No. 1)* Acumen Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of |
|
| February 14, 2023 |
ABOS / Acumen Pharmaceuticals, Inc. / Sands Capital Ventures, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO Section 240. |
|
| February 1, 2023 |
Exhibit 99.1 Corporate Presentation February 2023 1 Forward-Looking Statements This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Any statement describing Acumen’s goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Word |
|
| February 1, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 1, 2023 Acumen Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40551 36-4108129 (State or Other Jurisdiction of Incorporation) (Comm |
|
| January 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 3, 2023 Acumen Pharmaceuticals, Inc. (Exact name of registrant as specified in its Charter) Delaware 001-40551 36-4108129 (State or Other Jurisdiction of Incorporation) (Commi |
|
| November 14, 2022 |
Exhibit 99.2 Corporate Presentation November 2022 Forward-Looking Statements This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Any statement describing Acumen?s goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Words |
|
| November 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2022 Acumen Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40551 36-4108129 (State or Other Jurisdiction of Incorporation) (Com |
|
| November 14, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40551 Acumen Pharmaceuticals, Inc. |
|
| November 14, 2022 |
Acumen Pharmaceuticals Reports Third Quarter 2022 Financial Results and Business Highlights Exhibit 99.1 Acumen Pharmaceuticals Reports Third Quarter 2022 Financial Results and Business Highlights ? INTERCEPT-AD, a Phase 1 clinical trial of ACU193 in patients with early Alzheimer?s disease continues to progress ? Acumen anticipates completing enrollment in the first quarter of 2023 and reporting topline data from this trial in the second half of 2023 ? ACU193 was granted Fast Track desig |
|
| October 24, 2022 |
EX-99.1 Exhibit 99.1 Acumen’s ACU193, an Anti-Amyloid Beta Oligomer Antibody, Granted FDA Fast Track Designation for Alzheimer’s Disease Charlottesville, Va. and Carmel, Ind. (October 24, 2022) – Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) today announced that ACU193, the first clinical-stage monoclonal antibody that selectively targets toxic soluble amyloid beta oligomers (AßOs), has been granted |
|
| October 24, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 24, 2022 Acumen Pharmaceuticals, Inc. (Exact name of registrant as specified in its Charter) Delaware 001-40551 36-4108129 (State or Other Jurisdiction of Incorporation) (Comm |
|
| September 12, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 12, 2022 Acumen Pharmaceuticals, Inc. (Exact name of registrant as specified in its Charter) Delaware 001-40551 36-4108129 (State or Other Jurisdiction of Incorporation) (Co |
|
| September 12, 2022 |
Exhibit 99.1 Corporate Overview September 2022 1 Forward-Looking Statements This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Any statement describing Acumen?s goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Words s |
|
| August 15, 2022 |
Table of Contents Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40551 Acumen Pharmaceuticals, Inc. |
|
| August 15, 2022 |
Acumen Pharmaceuticals Reports Financial Results for Second Quarter 2022 and Business Highlights Exhibit 99.1 Acumen Pharmaceuticals Reports Financial Results for Second Quarter 2022 and Business Highlights ? Topline results expected in the first half of 2023 from INTERCEPT-AD, a multi-center, randomized, double-blind, placebo-controlled, single- and multiple-ascending dose Phase 1 clinical trial of ACU193 in patients with early Alzheimer?s disease (AD) ? Key methods and assay model developed |
|
| August 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2022 Acumen Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40551 36-4108129 (State or Other Jurisdiction of Incorporation) (Commi |
|
| August 1, 2022 |
Exhibit 99.1 Acumen presents poster describing method to standardize amyloid beta oligomer assays supporting therapeutic development for early Alzheimer?s disease Model designed to fill need for soluble amyloid beta oligomer reference standards in bioanalytical assays Charlottesville, Va. and Carmel, Ind. (August 1, 2022) ? Scientists at Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) have developed a |
|
| August 1, 2022 |
Exhibit 99.2 Preparation and qualification of soluble A?Os for use in bioanalytical assays supporting AD therapeutics Erika Cline1, Hugo Vanderstichele2*, Derrick Johnson3, Sanofar Jainul Abdeen3, Paul McDermott3, James Cruse3, Kirsten Viola4, Guus Scheefhals5, Robert Dean6, Jasna Jerecic1 1Acumen Pharmaceuticals, Charlottesville, VA, USA, 2Biomarkable, Gent, Belgium, 3B2S Life Sciences, Indianapo |
|
| August 1, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 1, 2022 Acumen Pharmaceuticals, Inc. (Exact name of registrant as specified in its Charter) Delaware 001-40551 36-4108129 (State or Other Jurisdiction of Incorporation) (Commis |
|
| July 6, 2022 |
ACUMEN PHARMACEUTICALS, INC. 427 Park St. Charlottesville, Virginia 22902 ACUMEN PHARMACEUTICALS, INC. 427 Park St. Charlottesville, Virginia 22902 July 6, 2022 Via EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Daniel Crawford Re: Acumen Pharmaceuticals, Inc. Registration Statement on Form S-3 (File No. 333-266004) Request for Acceleration of Effective Date Mr. Crawford: In accordance with R |
|
| July 1, 2022 |
Form of Preferred Stock Warrant Agreement and Warrant Certificate. EX-4.5 5 d372672dex45.htm EX-4.5 Exhibit 4.5 ACUMEN PHARMACEUTICALS, INC. AND , AS WARRANT AGENT FORM OF PREFERRED STOCK WARRANT AGREEMENT DATED AS OF ACUMEN PHARMACEUTICALS, INC. FORM OF PREFERRED STOCK WARRANT AGREEMENT This PREFERRED STOCK WARRANT AGREEMENT (this “Agreement”), dated as of [•], between ACUMEN PHARMACEUTICALS, INC., a Delaware corporation (the “Company”), and [•], a [corporation] |
|
| July 1, 2022 |
Form of Indenture, between the Registrant and one or more trustees to be named. Exhibit 4.2 ACUMEN PHARMACEUTICALS, INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [?], 20 Debt Securities TABLE OF CONTENTS PAGE ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 5 Section 2.01 Designation and Terms of Securities 5 Section 2.02 Form of Securities and Trustee?s Certificate |
|
| July 1, 2022 |
Exhibit 1.2 ACUMEN PHARMACEUTICALS, INC. Common Stock ($0.0001 par value) ATM EQUITY OFFERINGSM SALES AGREEMENT July 1, 2022 BofA Securities, Inc. Stifel, Nicolaus & Company, Incorporated c/o BofA Securities, Inc. One Bryant Park New York, New York 10036 c/o Stifel, Nicolaus & Company, Incorporated 787 Seventh Avenue, 11th Floor New York, New York 10019 Ladies and Gentlemen: Acumen Pharmaceuticals |
|
| July 1, 2022 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Acumen Pharmaceuticals, Inc. |
|
| July 1, 2022 |
Form of Debt Securities Warrant Agreement and Warrant Certificate. EX-4.6 6 d372672dex46.htm EX-4.6 Exhibit 4.6 ACUMEN PHARMACEUTICALS, INC. AND , AS WARRANT AGENT FORM OF DEBT SECURITIES WARRANT AGREEMENT DATED AS OF ACUMEN PHARMACEUTICALS, INC. FORM OF DEBT SECURITIES WARRANT AGREEMENT This DEBT SECURITIES WARRANT AGREEMENT (this “Agreement”), dated as of [•], between ACUMEN PHARMACEUTICALS, INC., a Delaware corporation (the “Company”), and [•], a [corporation] |
|
| July 1, 2022 |
As filed with the Securities and Exchange Commission on July 1, 2022 Table of Contents As filed with the Securities and Exchange Commission on July 1, 2022 Registration No. |
|
| July 1, 2022 |
Form of Common Stock Warrant Agreement and Warrant Certificate. Exhibit 4.4 ACUMEN PHARMACEUTICALS, INC. AND , AS WARRANT AGENT FORM OF COMMON STOCK WARRANT AGREEMENT DATED AS OF ACUMEN PHARMACEUTICALS, INC. FORM OF COMMON STOCK WARRANT AGREEMENT This COMMON STOCK WARRANT AGREEMENT (this ?Agreement?), dated as of [?], between ACUMEN PHARMACEUTICALS, INC., a Delaware corporation (the ?Company?), and [?], a [corporation] [national banking association] organized |
|
| June 21, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 15, 2022 Acumen Pharmaceuticals, Inc. (Exact name of registrant as specified in its Charter) Delaware 001-40551 36-4108129 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| May 16, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40551 Acumen Pharmaceuticals, Inc. |
|
| May 16, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 16, 2022 Acumen Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40551 36-4108129 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| May 16, 2022 |
Acumen Pharmaceuticals Reports Financial Results for First Quarter 2022 and Business Highlights Exhibit 99.1 Acumen Pharmaceuticals Reports Financial Results for First Quarter 2022 and Business Highlights ? Topline results expected in the first half of 2023 from INTERCEPT-AD, a multi-center, randomized, double-blind, placebo-controlled, single- and multiple-ascending dose Phase 1 clinical trial of ACU193 in patients with early Alzheimer?s disease ? Frontiers in Neuroscience recently publishe |
|
| April 27, 2022 |
Table of Contents SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| April 27, 2022 |
SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| March 29, 2022 |
As filed with the Securities and Exchange Commission on March 29, 2022 As filed with the Securities and Exchange Commission on March 29, 2022 Registration No. |
|
| March 29, 2022 |
Exhibit 107 CALCULATION OF FILING FEE TABLES Form S-8 Acumen Pharmaceuticals, Inc. |
|
| March 28, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 28, 2022 Acumen Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40551 36-4108129 (State or Other Jurisdiction of Incorporation) (Commis |
|
| March 28, 2022 |
Exhibit 10.9 AMENDED AND RESTATED EMPLOYMENT AGREEMENT This AMENDED AND RESTATED EMPLOYMENT AGREEMENT (the ?Agreement?) is entered into effective January 1, 2022 (the ?Effective Date?), by and between Eric Siemers, MD (the ?Executive?) and Acumen Pharmaceuticals, Inc. (the ?Company?) and supersedes and replaces any prior consulting agreement or employment letter between the Parties and any of thei |
|
| March 28, 2022 |
Non-Employee Director Compensation Policy Exhibit 10.3 ACUMEN PHARMACEUTICALS, INC. NON-EMPLOYEE DIRECTOR COMPENSATION POLICY ORIGINALLY ADOPTED BY THE BOARD OF DIRECTORS: Effective June 30, 2021 AMENDED BY THE BOARD OF DIRECTORS: March 24, 2022 Each member of the Board of Directors (the ?Board?) who is not also serving as an employee of or consultant to Acumen Pharmaceuticals, Inc. (the ?Company?) or any of its subsidiaries (each such me |
|
| March 28, 2022 |
Table of Contents Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| March 28, 2022 |
Exhibit 4.2 DESCRIPTION OF COMMON STOCK The following description of the common stock of Acumen Pharmaceuticals, Inc., or the Company, and certain provisions of the Company?s amended and restated certificate of incorporation and amended and restated bylaws, and certain provisions of Delaware law are summaries. These summaries are qualified in their entirety by reference to the provisions of the De |
|
| March 28, 2022 |
Exhibit 99.1 Acumen Pharmaceuticals Reports Financial Results for Full Year Ended December 31, 2021 and Business Highlights - Acumen is progressing ACU193, the first monoclonal antibody designed to selectively target toxic amyloid-beta oligomers (A?Os) to enter clinical testing - Currently enrolling INTERCEPT-AD, a multi-center, randomized, double-blind, placebo-controlled, single- and multiple-as |
|
| March 28, 2022 |
Employment Agreement by and between the Registrant and Russell Barton Exhibit 10.10 AMENDED AND RESTATED EMPLOYMENT AGREEMENT This AMENDED AND RESTATED EMPLOYMENT AGREEMENT (the ?Agreement?) is entered into effective January 1, 2022 (the ?Effective Date?), by and between Russell Barton (the ?Executive?) and Acumen Pharmaceuticals, Inc. (the ?Company?) and supersedes and replaces any prior consulting agreement or employment letter between the Parties and any of their |
|
| March 28, 2022 |
Exhibit 10.7 AMENDED AND RESTATED EMPLOYMENT AGREEMENT This AMENDED AND RESTATED EMPLOYMENT AGREEMENT (the ?Agreement?) is entered into effective January 1, 2022 (the ?Effective Date?), by and between Daniel J. O?Connell (the ?Executive?) and Acumen Pharmaceuticals, Inc. (the ?Company?) and supersedes and replaces any prior consulting agreement or employment letter between the Parties and any of t |
|
| March 28, 2022 |
Exhibit 10.8 AMENDED AND RESTATED EMPLOYMENT AGREEMENT This AMENDED AND RESTATED EMPLOYMENT AGREEMENT (the ?Agreement?) is entered into effective January 1, 2022 (the ?Effective Date?), by and between Wm. Matthew Zuga (the ?Executive?) and Acumen Pharmaceuticals, Inc. (the ?Company?) and supersedes and replaces any prior consulting agreement or employment letter between the Parties and any of thei |
|
| February 16, 2022 |
ABOS / Acumen Pharmaceuticals, Inc. / Hardie Molly G. - SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Acumen Pharmaceuticals, Inc. - (Name of Issuer) Common Stock, $0.0001 par value - (Title of Class of Securities) 00509G209 - (CUSIP Number) July 1, 2021 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the r |
|
| February 16, 2022 |
ABOS / Acumen Pharmaceuticals, Inc. / Hardie Molly G. - SCHEDULE 13G Passive Investment begin 644 schedule13G.pdf M)5!$1BTQ+C4*):;IS\0-"C0@,"!O8FH*/#P*+TQE;F=T:" U(# @4@HO1FEL M=&5R("]&;&%T941E8V]D90H^/@IS=')E86T-"GC:[5IMC]O&$?Y^OV)A%.@R ML%@NW]EO5OB.DBOJ>^"%$@"0Z\G)6=2UDEGY]]W9I[9%2G+CM2TWPX!K".Y MG)V=M^>98=Y?.WVXB]?.^-O*E'4:Y[FY?7?QHT^ MRNQU-"KBQKZ.7!D7]C8:-;&S5U$:E9EE-'?YH8N)>TD5M#:T,6\;3UZ0 M!JG]N^AQ*<*O2>57\M<5O5#3#B]DNW2FL;^(QIE\@^MUQUO(DW%OR[>?]9X:4&ZE:8LR889C/=#-&(#C*'V U]5=A |
|
| February 15, 2022 |
Paul B. Manning SC 13G Exhibit A EXHIBIT A JOINT FILING AGREEMENT Pursuant to Rule 13d-1(k)(1) promulgated pursuant to the Securities Exchange Act of 1934, as amended, the undersigned agree that the attached Schedule 13D is being filed on behalf of each of the undersigned. Dated: February 14, 2022 /s/ Paul B. Manning Paul B. Manning The Paul B. Manning Revocable Trust Dated May 10, 2000 By: /s/ Pa |
|
| February 15, 2022 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO ?240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO ?240.13d-2 (Amendment No. )* Acumen Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 00509G209 (CUSIP Number) December 31, 2 |
|
| February 14, 2022 |
ABOS / Acumen Pharmaceuticals, Inc. / MURRAY JAMES B JR - SC 13G Passive Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. |
|
| January 27, 2022 |
ABOS / Acumen Pharmaceuticals, Inc. / Deep Track Capital, LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| January 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 1, 2022 Acumen Pharmaceuticals, Inc. (Exact name of registrant as specified in its Charter) Delaware 001-40551 36-4108129 (State or Other Jurisdiction of Incorporation) (Commi |
|
| November 15, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40551 Acumen Pharmaceuticals, Inc. |
|
| November 15, 2021 |
Acumen Pharmaceuticals Reports Financial Results for Third Quarter 2021 and Business Highlights Exhibit 99.1 Acumen Pharmaceuticals Reports Financial Results for Third Quarter 2021 and Business Highlights ? Acumen?s investigational product candidate, ACU193, is the first humanized monoclonal antibody discovered and developed to selectively target toxic amyloid-beta oligomers (A?Os) to enter clinical trials ? Enrolled first patients in INTERCEPT-AD, a multi-center, randomized, double-blind, p |
|
| November 15, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 15, 2021 Acumen Pharmaceuticals, Inc. (Exact name of registrant as specified in its Charter) Delaware 001-40551 36-4108129 (State or Other Jurisdiction of Incorporation) (Com |
|
| November 10, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2021 Acumen Pharmaceuticals, Inc. (Exact name of registrant as specified in its Charter) Delaware 001-40551 36-4108129 (State or Other Jurisdiction of Incorporation) (Com |
|
| November 10, 2021 |
Overview of product candidate ACU193 and the ongoing Phase 1 INTERCEPT-AD trial November 2021 Exhibit 99. |
|
| October 7, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 7, 2021 Acumen Pharmaceuticals, Inc. (Exact name of registrant as specified in its Charter) Delaware 001-40551 36-4108129 (State or Other Jurisdiction of Incorporation) (Commi |
|
| October 7, 2021 |
Exhibit 99.1 Acumen Announces First Patient Dosed in a Phase 1 Clinical Trial of ACU193, a Monoclonal Antibody that Selectively Targets Toxic A? Oligomers for the Treatment of Early Alzheimer?s Disease. ACU193 is the first monoclonal antibody to enter a clinical trial that was discovered and is being developed to selectively target toxic amyloid-beta oligomers (A?Os). Enrollment of early Alzheimer |
|
| September 13, 2021 |
ABOS / Acumen Pharmaceuticals, Inc. / RA CAPITAL MANAGEMENT, L.P. - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Acumen Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 00509G209 (CUSIP Number) RA Capital Management, L.P. 200 Berkeley Street, 18th Floor Boston, MA 02116 Attn: Peter Kolchinsky Telephon |
|
| August 31, 2021 |
Corporate Overview 3Q 2021 Exhibit 99.1 Acumen Safe Harbor Statement NOTES REGARDING THIS PRESENTATION This presentation may contain ?forward-looking statements? within the meaning of the Private Securities Litigation Reform Act of 1995 relating to our business, operations, and financial conditions, including but not limited to current beliefs, expectations and assumptions regarding the future of |
|
| August 31, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 31, 2021 Acumen Pharmaceuticals, Inc. (Exact name of registrant as specified in its Charter) Delaware 001-40551 36-4108129 (State or Other Jurisdiction of Incorporation) (Commi |
|
| August 16, 2021 |
Acumen Pharmaceuticals Reports Financial Results for Second Quarter 2021 and Business Highlights Exhibit 99.1 Acumen Pharmaceuticals Reports Financial Results for Second Quarter 2021 and Business Highlights - Acumen?s investigational drug, ACU193, is the first humanized monoclonal antibody discovered and developed to selectively target toxic amyloid-beta oligomers (A?Os) to enter clinical trials - Initiated ACU-001, a multi-center, randomized, double-blind, placebo-controlled, single- and mul |
|
| August 16, 2021 |
Table of Contents Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40551 Acumen Pharmaceuticals, Inc. |
|
| August 16, 2021 |
Employment Agreement by and between the Registrant and Matthew Zuga. Exhibit 10.8 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (the ?Agreement?) is entered into effective May 15, 2021 (the ?Effective Date?), by and between Wm. Matthew Zuga (the ?Executive?) and Acumen Pharmaceuticals, Inc. (the ?Company?) and supersedes and replaces any prior consulting agreement or employment letter between the Parties and any of their affiliates, including that certain Consulti |
|
| August 16, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 16, 2021 Acumen Pharmaceuticals, Inc. (Exact name of registrant as specified in its Charter) Delaware 001-40551 36-4108129 (State or Other Jurisdiction of Incorporation) (Commi |
|
| July 16, 2021 |
EX-99.1 2 tm2122363d1ex99-1.htm EXHIBIT 99.1 Exhibit 1 JOINT FILING AGREEMENT This Joint Filing Agreement, dated as of July 16, 2021, is by and among RA Capital Management, L.P., Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P. (the foregoing are collectively referred to herein as the “Filers”). Each of the Filers may be required to file with the United States Securities and Exc |
|
| July 16, 2021 |
ABOS / Acumen Pharmaceuticals, Inc. / RA CAPITAL MANAGEMENT, L.P. - SCHEDULE 13D Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment )* Acumen Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 00509G209 (CUSIP Number) RA Capital Management, L.P. 200 Berkeley Street, 18th Floor Boston, MA 02116 Attn: Peter Kolchinsky Telephone: 617.778.2500 (Name |
|
| July 13, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to ? 240. |
|
| July 7, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 6, 2021 Acumen Pharmaceuticals, Inc. (Exact name of registrant as specified in its Charter) Delaware 001-40551 36-4108129 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| July 7, 2021 |
Exhibit 3.1 ACUMEN PHARMACEUTICALS, INC. AMENDED AND RESTATED CERTIFICATE OF INCORPORATION Acumen Pharmaceuticals, Inc., a corporation organized and existing under the laws of the State of Delaware (the ?Company?), does hereby certify as follows: FIRST: That the name of this corporation is Acumen Pharmaceuticals, Inc. The original Certificate of Incorporation of the Company was filed with the Dela |
|
| July 7, 2021 |
Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF ACUMEN PHARMACEUTICALS, INC. (A DELAWARE CORPORATION) July 6, 2021 ACUMEN PHARMACEUTICALS, INC. AMENDED AND RESTATED BYLAWS ARTICLE I OFFICES Section 1. Registered Office. The registered office shall be established and maintained at the office of Corporation Service Company, 251 Little Falls Drive, in the city of Wilmington, county of New Castle, Delaware |
|
| July 2, 2021 |
As filed with the U.S. Securities and Exchange Commission on July 2, 2021 As filed with the U.S. Securities and Exchange Commission on July 2, 2021 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ACUMEN PHARMACEUTICALS, INC. (Exact name of Registrant as specified in its charter) Delaware 36-4108129 (State or other jurisdiction of Incorporation or organization) |
|
| July 2, 2021 |
Table of Contents Filed Pursuant to Rule 424(b)(4) Registration Nos. 333-256945 and 333-257587 9,999,999 Shares Common Stock This is Acumen Pharmaceuticals, Inc.?s initial public offering. We are selling 9,999,999 shares of our common stock. The initial public offering price is $16.00 per share. Prior to this offering, no public market existed for the shares of our common stock. Our common stock h |
|
| June 30, 2021 |
As filed with the Securities and Exchange Commission on June 30, 2021 As filed with the Securities and Exchange Commission on June 30, 2021 Registration No. |
|
| June 28, 2021 |
ACUMEN PHARMACEUTICALS, INC. 427 Park Street Charlottesville, Virginia 22902 June 28, 2021 VIA EDGAR ACUMEN PHARMACEUTICALS, INC. 427 Park Street Charlottesville, Virginia 22902 June 28, 2021 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Jeanne Bennett Mary Mast David Gessert Celeste Murphy RE: Acumen Pharmaceuticals, Inc. Registration Statement on Form S-1 File No. 333-256945 Acceleration Request Request |
|
| June 28, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 Acumen Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 36-4108129 (State of incorporation or organization) (I.R.S. Employer Identification No.) 427 Park St., C |
|
| June 28, 2021 |
June 28, 2021 VIA EDGAR AND EMAIL United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| June 24, 2021 |
Certificate of Amendment to Amended and Restated Certificate of Incorporation Exhibit 3.5 CERTIFICATE OF AMENDMENT TO AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF ACUMEN PHARMACEUTICALS, INC. Acumen Pharmaceuticals, Inc. (the ?Corporation?), a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the ?General Corporation Law?), does hereby certify as follows: 1. The name of this corporation |
|
| June 24, 2021 |
Exhibit 10.6 ACUMEN PHARMACEUTICALS, INC. INDEMNIFICATION AGREEMENT This Indemnification Agreement (this ?Agreement?) is dated as of , and is between Acumen Pharmaceuticals, Inc., a Delaware corporation (the ?Company?), and (?Indemnitee?). RECITALS A. Indemnitee?s service to the Company substantially benefits the Company. B. Individuals are reluctant to serve as directors or officers of corporatio |
|
| June 24, 2021 |
2021 Employee Stock Purchase Plan Exhibit 10.4 ACUMEN PHARMACEUTICALS, INC. 2021 EMPLOYEE STOCK PURCHASE PLAN ADOPTED BY THE BOARD OF DIRECTORS: JUNE 22, 2021 APPROVED BY THE STOCKHOLDERS: JUNE 22, 2021 1. GENERAL; PURPOSE. (a) The Plan provides a means by which Eligible Employees of the Company and certain designated Related Corporations may be given an opportunity to purchase shares of Common Stock. The Plan permits the Company |
|
| June 24, 2021 |
Exhibit 10.1 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. AMENDED AND RESTATED COLLABORATION AGREEMENT This AMENDED AND RESTATED COLLABORATION AGREEMENT (the ?Agreement?), effective as of December 22, 2003, as amended and restated as of O |
|
| June 24, 2021 |
Cooley LLP 11951 Freedom Dr. #1500 Reston, VA 20190 t: (703) 456-8039 f: (703) 456-8100 cooley.com Darren DeStefano + 703 456 8034 [email protected] June 24, 2021 U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Attn: Jeanne Bennett Mary Mast David Gessert Celeste Murphy Re: Acumen Pharmaceuticals, Inc. Registration Statement on Form S-1 Filed June 9, 2021 File No. 333-256945 Ladies and Gentlemen: On behalf of Acumen Pharmaceuti |
|
| June 24, 2021 |
Exhibit 10.2 ACUMEN PHARMACEUTICALS, INC. 2021 EQUITY INCENTIVE PLAN Adopted by the Board of Directors: June 22, 2021 Approved by the Stockholders: June 22, 2021 TABLE OF CONTENTS Page 1. GENERAL. 1 2. SHARES SUBJECT TO THE PLAN. 1 3. ELIGIBILITY AND LIMITATIONS. 2 4. OPTIONS AND STOCK APPRECIATION RIGHTS. 3 5. AWARDS OTHER THAN OPTIONS AND STOCK APPRECIATION RIGHTS. 7 6. ADJUSTMENTS UPON CHANGES |
|
| June 24, 2021 |
Power of Attorney of Nathan B. Fountain, M.D. Exhibit 24.2 Acumen Pharmaceuticals, Inc. Power of Attorney I hereby appoint Daniel O?Connell and William Matthew Zuga, and each of them, as my true and lawful agents, proxies and attorneys-in-fact, with full power of substitution and resubstitution, to act in my name, place and stead, in any and all capacities, to (i) act on, sign and file with the Securities and Exchange Commission any and all a |
|
| June 24, 2021 |
Non-Employee Director Compensation Policy Exhibit 10.3 ACUMEN PHARMACEUTICALS, INC. NON-EMPLOYEE DIRECTOR COMPENSATION POLICY Each member of the Board of Directors (the ?Board?) who is not also serving as an employee of or consultant to Acumen Pharmaceuticals, Inc. (the ?Company?) or any of its subsidiaries (each such member, an ?Eligible Director?) will receive the compensation described in this Non-Employee Director Compensation Policy |
|
| June 24, 2021 |
Amended and Restated Certificate of Incorporation of the Registrant. Exhibit 3.3 ACUMEN PHARMACEUTICALS, INC. AMENDED AND RESTATED CERTIFICATE OF INCORPORATION Acumen Pharmaceuticals, Inc., a corporation organized and existing under the laws of the State of Delaware (the ?Company?), does hereby certify as follows: FIRST: That the name of this corporation is Acumen Pharmaceuticals, Inc. The original Certificate of Incorporation of the Company was filed with the Dela |
|
| June 24, 2021 |
Form of Underwriting Agreement Exhibit 1.1 ACUMEN PHARMACEUTICALS, INC. (a Delaware corporation) [?] Shares of Common Stock UNDERWRITING AGREEMENT Dated: [?], 2021 ACUMEN PHARMACEUTICALS, INC. (a Delaware Corporation) [?] Shares of Common Stock UNDERWRITING AGREEMENT [?], 2021 BofA Securities, Inc. Credit Suisse Securities (USA) LLC Stifel, Nicolaus & Company, Incorporated as Representatives of the several Underwriters c/o BofA |
|
| June 24, 2021 |
Amended and Restated Bylaws of the Registrant. Exhibit 3.4 AMENDED AND RESTATED BYLAWS OF ACUMEN PHARMACEUTICALS, INC. (A DELAWARE CORPORATION) , 2021 ACUMEN PHARMACEUTICALS, INC. AMENDED AND RESTATED BYLAWS ARTICLE I OFFICES Section 1. Registered Office. The registered office shall be established and maintained at the office of Corporation Service Company, 251 Little Falls Drive, in the city of Wilmington, county of New Castle, Delaware 19808 |
|
| June 24, 2021 |
As filed with the Securities and Exchange Commission on June 24, 2021. Table of Contents As filed with the Securities and Exchange Commission on June 24, 2021. |
|
| June 16, 2021 |
Darren K. DeStefano VIA EDGAR +1 703 456 8034 [email protected] *FOIA Confidential Treatment Request* Confidential Treatment Requested by Acumen Pharmaceuticals, Inc. in connection with its Registration Statement on Form S-1 (File No. 333-256945) June 16, 2021 U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Jeanne Bennett |
|
| June 9, 2021 |
Table of Contents As filed with the Securities and Exchange Commission on June 9, 2021. |
|
| June 9, 2021 |
Exhibit 10.1 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. AMENDED AND RESTATED COLLABORATION AGREEMENT This AMENDED AND RESTATED COLLABORATION AGREEMENT (the ?Agreement?), effective as of December 22, 2003, as amended and restated as of O |
|
| June 9, 2021 |
Amended and Restated Bylaws of the Registrant (currently in effect) Exhibit 3.2 AMENDED AND RESTATED BY-LAWS OF ACUMEN PHARMACEUTICALS, INC. (A Delaware corporation) ARTICLE 1 OFFICES: REGISTERED AGENT ? 1 Registered Office and Agent. The corporation shall maintain in the State of Delaware a registered office and a registered agent whose business office is identical with such registered office. ? 2 Principal Business Office. The corporation shall have its principa |
|
| June 9, 2021 |
Employment Agreement by and between the Registrant and Russell Barton Exhibit 10.9 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (the ?Agreement?) is entered into effective January 1, 2021 (the ?Effective Date?), by and between Russell Barton (the ?Executive?) and Acumen Pharmaceuticals, Inc. (the ?Company?) and supersedes and replaces any prior consulting agreement or employment letter between the Parties and any of their affiliates. WHEREAS, the Company desires t |
|
| June 9, 2021 |
Exhibit 4.1 AMENDED AND RESTATED INVESTORS? RIGHTS AGREEMENT THIS AMENDED AND RESTATED INVESTORS? RIGHTS AGREEMENT (this ?Agreement?), is made as of November 20, 2020, by and among ACUMEN PHARMACEUTICALS, INC., a Delaware corporation (the ?Company?), each of the investors listed on Schedule A hereto, each of which is referred to in this Agreement as an ?Investor? and any Additional Purchaser (as d |
|
| June 9, 2021 |
Exhibit 10.5 ACUMEN PHARMACEUTICALS, INC. AMENDED AND RESTATED STOCK PERFORMANCE PLAN Section 1. Purposes of the Plan. The purposes of this Plan are to promote the interests of the Company and its stockholders by using equity interests in the Company to attract, retain and motive its management and other persons and to encourage and reward their contributions to the performance of the Company. Cer |
|
| June 9, 2021 |
Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF ACUMEN PHARMACEUTICALS, INC. (Pursuant to Sections 242 and 245 of the General Corporation Law of the State of Delaware) Acumen Pharmaceuticals, Inc., a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the ?General Corporation Law?), DOES HEREBY CERTIFY: |
|
| June 9, 2021 |
Employment Agreement by and between the Registrant and Eric Siemers, M.D. Exhibit 10.8 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (the ?Agreement?) is entered into effective January 1, 2021 (the ?Effective Date?), by and between Eric Siemers, MD (the ?Executive?) and Acumen Pharmaceuticals, Inc. (the ?Company?) and supersedes and replaces any prior consulting agreement or employment letter between the Parties and any of their affiliates. WHEREAS, the Company desires |
|
| June 9, 2021 |
Cooley LLP 11951 Freedom Dr. #1500 Reston, VA 20190 t: (703) 456-8039 f: (703) 456-8100 cooley.com Darren DeStefano + 703 456 8034 [email protected] June 9, 2021 U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Attn: Jeanne Bennett Mary Mast David Gessert Celeste Murphy Re: Acumen Pharmaceuticals, Inc. Amendment No. 1 to Draft Registration Statement on Form S-1 Submitted May 14, 2021 CIK No. 0001576885 Ladies and Gentlemen: On b |
|
| June 9, 2021 |
Executive Employment Agreement, by and between the Registrant and Daniel O’Connell Exhibit 10.7 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (the ?Agreement?) is entered into effective January 1, 2021 (the ?Effective Date?), by and between Daniel J. O?Connell (the ?Executive?) and Acumen Pharmaceuticals, Inc. (the ?Company?) and supersedes and replaces any prior consulting agreement or employment letter between the Parties and any of their affiliates. WHEREAS, the Company desi |
|
| June 3, 2021 |
As submitted to the Securities and Exchange Commission confidentially on June 3, 2021. |
|
| June 3, 2021 |
AMENDED AND RESTATED COLLABORATION AGREEMENT Exhibit 10.1 CONFIDENTIAL CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. AMENDED AND RESTATED COLLABORATION AGREEMENT This AMENDED AND RESTATED COLLABORATION AGREEMENT (the ?Agreement?), effective as of December 22, 2003, as amended and res |
|
| May 14, 2021 |
AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT Exhibit 4.1 AMENDED AND RESTATED INVESTORS? RIGHTS AGREEMENT THIS AMENDED AND RESTATED INVESTORS? RIGHTS AGREEMENT (this ?Agreement?), is made as of November 20, 2020, by and among ACUMEN PHARMACEUTICALS, INC., a Delaware corporation (the ?Company?), each of the investors listed on Schedule A hereto, each of which is referred to in this Agreement as an ?Investor? and any Additional Purchaser (as d |
|
| May 14, 2021 |
Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF ACUMEN PHARMACEUTICALS, INC. (Pursuant to Sections 242 and 245 of the General Corporation Law of the State of Delaware) Acumen Pharmaceuticals, Inc., a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the ?General Corporation Law?), DOES HEREBY CERTIFY: |
|
| May 14, 2021 |
Exhibit 10.9 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (the ?Agreement?) is entered into effective January 1, 2021 (the ?Effective Date?), by and between Russell Barton (the ?Executive?) and Acumen Pharmaceuticals, Inc. (the ?Company?) and supersedes and replaces any prior consulting agreement or employment letter between the Parties and any of their affiliates. WHEREAS, the Company desires t |
|
| May 14, 2021 |
Exhibit 10.7 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (the ?Agreement?) is entered into effective January 1, 2021 (the ?Effective Date?), by and between Daniel J. O?Connell (the ?Executive?) and Acumen Pharmaceuticals, Inc. (the ?Company?) and supersedes and replaces any prior consulting agreement or employment letter between the Parties and any of their affiliates. WHEREAS, the Company desi |
|
| May 14, 2021 |
Exhibit 3.2 AMENDED AND RESTATED BY-LAWS OF ACUMEN PHARMACEUTICALS, INC. (A Delaware corporation) ARTICLE 1 OFFICES: REGISTERED AGENT ? 1 Registered Office and Agent. The corporation shall maintain in the State of Delaware a registered office and a registered agent whose business office is identical with such registered office. ? 2 Principal Business Office. The corporation shall have its principa |
|
| May 14, 2021 |
Exhibit 10.8 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (the ?Agreement?) is entered into effective January 1, 2021 (the ?Effective Date?), by and between Eric Siemers, MD (the ?Executive?) and Acumen Pharmaceuticals, Inc. (the ?Company?) and supersedes and replaces any prior consulting agreement or employment letter between the Parties and any of their affiliates. WHEREAS, the Company desires |
|
| May 14, 2021 |
Cooley LLP 11951 Freedom Dr. #1500 Reston, VA 20190 t: (703) 456-8039 f: (703) 456-8100 cooley.com Darren DeStefano + 703 456 8034 [email protected] May 14, 2021 U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Attn: Jeanne Bennett Mary Mast David Gessert Celeste Murphy Re: Acumen Pharmaceuticals, Inc. Draft Registration Statement on Form S-1 Submitted April 12, 2021 CIK No. 0001576885 Ladies and Gentlemen: On behalf of Acumen P |
|
| May 14, 2021 |
DRS/A 1 filename1.htm Table of Contents As submitted to the Securities and Exchange Commission confidentially on May 14, 2021. This draft registration statement has not been publicly filed with the Securities and Exchange Commission and all information herein remains strictly confidential. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGIST |
|
| April 12, 2021 |
Table of Contents As submitted to the Securities and Exchange Commission confidentially on April 12, 2021. |
